Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

forces of nature - urtica dioica (unii: 710flw4u46) (urtica dioica - unii:710flw4u46) - treats skin rashes and itchy burning skin. use to fight, reduce, and help eliminate seborrheic dermatitis and dandruff. controls the symptoms of seborrheic dermatitis or dandruff. treats itching, irritation, redness, and flaking of the skin or scalp.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

forces of nature - hamamelis virginiana root bark/stem bark (unii: t7s323pkjs) (hamamelis virginiana root bark/stem bark - unii:t7s323pkjs), horse chestnut (unii: 3c18l6rjaz) (horse chestnut - unii:3c18l6rjaz) - for the relief of inflammation, pain, itching and redness associated with hemorrhoids.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

forces of nature - thuja occidentalis leafy twig (unii: 1nt28v9397) (thuja occidentalis leafy twig - unii:1nt28v9397) - remedy for rosacea. treats skin rashes. relieves and controls the symptoms of rosacea. eases itching, irritation, redness, and flaking of the skin or scalp.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

forces of nature - calendula officinalis flowering top (unii: 18e7415pxq) (calendula officinalis flowering top - unii:18e7415pxq), silicon dioxide (unii: etj7z6xbu4) (silicon dioxide - unii:etj7z6xbu4) - for the relief and treatment of pain, soreness and inflammation from nail fungus.

Singapur - inglise - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - hepatitis a virus inactivated - injection - 720 elisa units/0.5ml - hepatitis a virus inactivated 720 elisa units/0.5ml

Singapur - inglise - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - hepatitis a virus (inactivated) - injection - 1440 elisa units/ml - hepatitis a virus (inactivated) 1440 elisa units/ml

Malaisia - inglise - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline pharmaceutical sdn. bhd. - hepatitis a viral antigen -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis a virus antigen; hepatitis b surface antigen recombinant -

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis a vaccine 1440 eu/ml;  ; hepatitis a vaccine 1440 eu/ml - suspension for injection - 1440 eu/ml - active: hepatitis a vaccine 1440 eu/ml   excipient: aluminium hydroxide amino acids dibasic sodium phosphate dihydrate monobasic potassium phosphate polysorbate 20 potassium chloride sodium chloride active: hepatitis a vaccine 1440 eu/ml excipient: aluminium hydroxide amino acids dibasic sodium phosphate dihydrate monobasic potassium phosphate phenoxyethanol polysorbate 20 potassium chloride sodium chloride - havrix is indicated for active immunisation against hav infection in subjects at risk of exposure to hav. havrix will not prevent hepatitis infection caused by other agents such as hepatitis b virus, hepatitis c virus, hepatitis e virus or other pathogens known to infect the liver. in areas of low and intermediate prevalence of hepatitis a, immunisation with havrix is particularly recommended in subjects who are, or will be, at increased risk of infection.

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis a vaccine 1440 eu/ml equivalent to 720 eu/0.5 ml;  ; hepatitis a vaccine 1440 eu/ml equivalent to 720 eu/0.5ml - suspension for injection - 720 elisa u/0.5ml - active: hepatitis a vaccine 1440 eu/ml equivalent to 720 eu/0.5 ml   excipient: aluminium hydroxide amino acids dibasic sodium phosphate dihydrate monobasic potassium phosphate polysorbate 20 potassium chloride sodium chloride active: hepatitis a vaccine 1440 eu/ml equivalent to 720 eu/0.5ml excipient: aluminium hydroxide amino acids dibasic sodium phosphate dihydrate monobasic potassium phosphate phenoxyethanol polysorbate 20 potassium chloride sodium chloride - havrix is indicated for active immunisation against hav infection in subjects at risk of exposure to hav. havrix will not prevent hepatitis infection caused by other agents such as hepatitis b virus, hepatitis c virus, hepatitis e virus or other pathogens known to infect the liver. in areas of low and intermediate prevalence of hepatitis a, immunisation with havrix is particularly recommended in subjects who are, or will be, at increased risk of infection.